NEW YORK — True Diagnostics has partnered with Veravas and Infectolab Americas to develop and commercialize a rapid, point-of-care immunoassay for SARS-CoV-2, the companies said on Thursday.
According to the partners, the VeraTest SARS-CoV-2 IgA/IgG Rapid Test will be designed to detect immunoglobulin A and immunoglobulin G antibodies against SARS-CoV-2 in blood within 15 minutes.
The test will combine True Diagnostics' TrueDx lateral flow immunoassay technology with Veravas' VeraPrep clean and VeraPrep capture technologies, which are designed to remove cross-reacting antibodies and ensure detection of only antibodies that are specific to SARS-CoV-2. Oakdale, Minnesota-based Infectolab, which specializes in tick-borne infection testing, will contribute its CLIA lab validation capabilities and infectious disease expertise.
Additional terms of the alliance were not disclosed.
In September, Carlsbad, California-based True Diagnostics and Charleston, South Carolina-based Veravas began working together on a portable test for rapidly screening patient samples for levels of biotin that could affect the accuracy of diagnostic tests.